Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Portlock, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Portlock, C. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1329-1330, 2002
© 2002 European Society for Medical Oncology

Editorial

Dose density and dose intensity: where does CHOP go from here?

C. S. Portlock

Attending Physician, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room H-819, New York, NY 10021, USA (E-mail: portlocc@mskcc.org)

The first 10% of the full text of this article appears below.

Non-myeloablative chemotherapy regimens have not been fully explored in the treatment of aggressive non-Hodgkin’s lymphomas [1]. Two important concepts in the development of new chemotherapy regimens are dose intensity [dose of effective drug administered per unit time (mg/m2/week), calculated per week even when the agent is administered once every 3 weeks as in CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)] and dose density (the frequency of effective drug dose administered) [2, 3]. In aggressive non-Hodgkin’s lymphomas, myeloablative dose intensity has been successfully established in the autologous stem . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
K. Tsukasaki, A. Utsunomiya, H. Fukuda, T. Shibata, T. Fukushima, Y. Takatsuka, S. Ikeda, M. Masuda, H. Nagoshi, R. Ueda, et al.
VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801
J. Clin. Oncol., December 1, 2007; 25(34): 5458 - 5464.
[Abstract] [Full Text] [PDF]